24653-89-2

Upstream product

• 19393-92-1 1-bromo-2,6-dichlorobenzene 
• 83-38-5 2,6-dichlorobenzaldehyde 
• 6575-25-3 1,3-dichloro-2-ethynyl-benzene 
• 541-41-3 chloroformic acid ethyl ester 

Downstream Products

• 27025-71-4 5-(2,6-dichloro-phenyl)-isoxazol-3-one 
• 1268245-61-9 C₁₄H₁₅Cl₂N₃O₂ 
• 1268245-67-5 C₁₂H₁₂Cl₃N₃ 
• 1268245-64-2 C₁₂H₁₃Cl₂N₃O 
• 27025-95-2 5-(2,6-dichloro-phenyl)-3-methoxy-isoxazole-4-carboxylic acid 
• 27025-82-7 5-(2,6-dichloro-phenyl)-2-methyl-isoxazol-3-one 
• 27025-77-0 5-(2,6-dichloro-phenyl)-3-methoxy-isoxazole 

Relevant academic research and scientific papers

HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC MUTAGENIC AND FIBROTIC CONDITIONS AND DISORDERS

The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): wherein L1, A, X1

NOVEL FXR (NR1H4 ) BINDING AND ACTIVITY MODULATING COMPOUNDS

The present invention relates to compounds which bind to the NR1 H4 receptor (FXR) and act as agonists of the NR1 H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds, and to a process for the synthesis of said compounds.